Skip to content
AnalystLens

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Jun 10, 2026)

Reports
Regulation FD
Filing Date
Filed June 10, 2026
Period End
June 10, 2026
Security
ELV
In the record · 2016–202610-K1110-Q348-K133

ELV filed 11 annual reports (10-K), 34 quarterly reports (10-Q) and 133 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Aug ’21Aug ’21
  2. Leadership change8-K · Jul ’25Jul ’25

01—Abstract

Summary

Summary of the 8-K filed June 10, 2026. Cited figures are marked; the original filing is the authoritative source.

Elevance Health, Inc. (ELV) issued an 8-K filing on June 10, 2026, to reaffirm its financial guidance for the full year 2026.

The company expects shareholders' earnings per diluted share to be at least $19.85a, which includes approximately $6.90 per diluted share from net unfavorable items. Excluding these items, the adjusted shareholders' earnings are projected to be at least $26.75 per diluted share, consistent with expectations set in the first quarter of 2026. This guidance does not incorporate any further adjustment items beyond those already reported.

Additionally, Elevance Health is reiterating its full-year 2026 guidance for the benefit expense ratio, which is expected to be 90.2%b plus or minus 50 basis points. This filing serves as a communication with investors and analysts, confirming the company's financial outlook and operational expectations for the remainder of the fiscal year.

02—Key points

Key Highlights

  1. Reaffirmed full-year 2026 shareholders' earnings guidance of at least $19.85 per diluted share.
  2. Confirmed adjusted shareholders' earnings guidance of at least $26.75 per diluted share for full-year 2026.
  3. Net unfavorable items are expected to impact earnings by approximately $6.90 per diluted share for 2026.
  4. Reiterated full-year 2026 benefit expense ratio guidance of 90.2% +/- 50 basis points.
  5. Guidance reaffirms previously stated financial expectations and does not include new adjustment items beyond Q1 2026.
  6. Filing is a Regulation FD disclosure intended for investor and analyst meetings.
  7. Standard forward-looking statements disclaimer included, highlighting potential risks and uncertainties.

03—Questions

Frequently Asked Questions

  1. What is the main purpose of this 8-K filing?

    The primary purpose of this 8-K filing is for Elevance Health, Inc. to reaffirm its previously issued financial guidance for the full fiscal year 2026 to investors and analysts during upcoming meetings.

  2. What is Elevance Health's updated earnings per share guidance for 2026?

    Elevance Health is reaffirming its guidance for full-year 2026 shareholders' earnings to be at least $19.85 per diluted share. This includes approximately $6.90 per diluted share from net unfavorable items. Excluding these items, the adjusted earnings per diluted share are expected to be at least $26.75.

  3. What is the company's outlook for its benefit expense ratio in 2026?

    The company is also reaffirming its full-year 2026 guidance for the benefit expense ratio, projecting it to be 90.2% plus or minus 50 basis points.

  4. Are there any new financial expectations or significant changes in this filing?

    No, this filing specifically states that the company is reaffirming its existing guidance and that it does not include any other adjustment items beyond those reported in the first quarter of 2026. The forward-looking statements section outlines potential risks but does not introduce new financial guidance.

04—Continue

← View all 8-K filings